End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 910-915

  Barnes, J A ^a,b   LaCasce, A S ^b,c   Zukotynski, K ^b,c   Israel, D ^b,c   Feng, Y ^c   Neuberg, D ^c,d   Toomey, C E ^a   Hochberg, E P ^a,b   Canellos, G P ^b,c   Abramson, J S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

FDG PET; HL; Hodgkin's disease; Interim; Prognosis; Staging

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 79953297062     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq549     Document Type: Article

References (19)

1. Ferme C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357(19): 1916-1927.
2. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327(21): 1478-1484.
3. Meyer RM, Gospodarowicz MK, Connors JM et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23(21): 4634-4642.
4. Federico M, Luminari S, Iannitto E et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27(5): 805-811.
5. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25(24): 3746-3752.
6. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107(1): 52-59.
7. Zinzani PL, Tani M, Fanti S et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17(8): 1296-1300.
8. Advani R, Maeda L, Lavori P et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 2007; 25(25): 3902-3907.
9. Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112(10): 3989-3994.
10. Furth C, Steffen IG, Amthauer H et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol 2009; 27(26): 4385-4391.
11. Noordijk EM, Carde P, Dupouy N et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24(19): 3128-3135.
12. Bonadonna G, Bonfante V, Viviani S et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22(14): 2835-2841.
13. Hutchings M, Mikhaeel NG, Fields PA et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16(7): 1160-1168.
14. Straus DJ, Portlock CS, Qin J et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104(12): 3483-3489.
15. Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010; 28(9): 1611-1615.
16. Rueda A, Olmos D, Viciana R, Alba E. Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment. Clin Lymphoma Myeloma 2006; 6(5): 389-392.
17. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5): 579-586.
18. Lister TA et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7(11): 1630-1636.
19. Moskowitz CH, Schoder H, Teruya-Feldstein J et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010; 28(11): 1896-1903.